A. Arenas-Pinto

发表

The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.

S. Walker, M. Sculpher, D. Dunn, 2016, Health technology assessment.

Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus–positive Patients Treated With Protease Inhibitor Monotherapy

X. Golay, M. Cardoso, L. Haddow, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brain perfusion, regional volumes and cognitive function in HIV positive patients treated with protease inhibitor monotherapy.

X. Golay, M. Cardoso, L. Haddow, 2018 .

Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross‐sectional and longitudinal analyses

L. Haddow, A. Phillips, F. Lampe, 2021, HIV medicine.

Baseline prevalence and predictors of liver fibrosis among HIV‐positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

J. Neuhaus, J. Rockstroh, S. Bhagani, 2015, HIV medicine.

Risky Alcohol Consumption and Associated Health Behaviour Among HIV-Positive and HIV-Negative Patients in a UK Sexual Health and HIV Clinic: A Cross-Sectional Questionnaire Study

A. Milinkovic, A. Arenas-Pinto, R. Matthews, 2019, AIDS and Behavior.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Risk factors for fatality in HIV-infected patients with NRTI-induced severe hyperlactataemia or lactic acidosis

R. Weber, A. Copas, P. Reiss, 2012 .

Risk Factors for Fatality in HIV-Infected Patients with Dideoxynucleoside-Induced Severe Hyperlactataemia or Lactic Acidosis

R. Weber, A. Copas, P. Reiss, 2011, Antiviral Therapy.

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)

D. Hawkins, A. Copas, A. Milinkovic, 2017, The Journal of antimicrobial chemotherapy.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

Platelet dysfunction-eosinophilia syndrome in parasitized Venezuelan children.

A. Arenas-Pinto, A. Ruiz-Sáez, G. Certad, 2005, The American journal of tropical medicine and hygiene.

Lipid changes due to tenofovir alafenamide are reversible by switching back to tenofovir disoproxil fumarate.

A. Milinkovic, S. Mauss, A. Arenas-Pinto, 2019, AIDS.

Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial

S. Emery, C. Stephan, A. Arenas-Pinto, 2019, Hepatology.

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

B. Clotet, A. Antinori, A. Clarke, 2015, AIDS.

Results of the clinical trial

S. Walker, M. Sculpher, D. Dunn, 2016 .

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial

J. Seeley, A. Walker, N. Klein, 2018 .

Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy

C. Leen, A. Winston, C. Orkin, 2013, PloS one.

Lactic acidosis in HIV infected patients: a systematic review of published cases

I. Weller, A. Grant, A. Arenas-Pinto, 2002, Sexually transmitted infections.

Isosporiasis in Venezuelan adults infected with human immunodeficiency virus: clinical characterization.

A. Arenas-Pinto, G. Ferrara, G. Certad, 2003, The American journal of tropical medicine and hygiene.

Cryptosporidiosis in HIV-infected Venezuelan adults is strongly associated with acute or chronic diarrhea.

A. Arenas-Pinto, G. Ferrara, G. Certad, 2005, The American journal of tropical medicine and hygiene.

SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

A. Schätzlein, K. Pyrć, A. Milewska, 2021, Scientific Reports.

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

A. Schätzlein, K. Pyrć, A. Milewska, 2020, bioRxiv.

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

P. Klenerman, T. Reynolds, M. Beekes, 2021, The Lancet.

Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials

A. Arenas-Pinto, J. Peraire, H. Knobel, 2020, HIV medicine.

NETWORK META-ANALYSIS OF POSTEXPOSURE PROPHYLAXIS RANDOMIZED CLINICAL TRIALS.

Lorna, A. Arenas-Pinto, E. Lazzari, 2020 .

Safety and Efficacy of Didanosine Enteric-Coated Capsule in Patients with HIV-1 Infection

A. Arenas-Pinto, 2009 .

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

A. Winston, M. Johnson, M. Gompels, 2015, The lancet. HIV.

The Risk of Developing Peripheral Neuropathy Induced by Nucleoside Reverse Transcriptase Inhibitors Decreases over Time: Evidence from the Delta Trial

I. Weller, D. Dunn, A. Arenas-Pinto, 2008, Antiviral therapy.

Human immunotypes impose selection on viral genotypes through viral epitope specificity.

H. Günthard, H. Lane, J. Lundgren, 2021, The Journal of infectious diseases.

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Scott L. Bain, A. Gibson, P. Klenerman, 2021, The Lancet.

Association between parasitic intestinal infections and acute or chronic diarrhoea in HIV-infected patients in Caracas, Venezuela

A. Arenas-Pinto, G. Certad, M. Bello, 2003, International journal of STD & AIDS.

Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related Factors.

A. Winston, D. Gibb, A. Arenas-Pinto, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Factors Associated With Nonadherence to Antiretroviral Therapy Among Young People Living With Perinatally Acquired HIV in England

A. Winston, D. Gibb, A. Arenas-Pinto, 2020, The Journal of the Association of Nurses in AIDS Care : JANAC.

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy

A. Tostevin, D. Dunn, N. Paton, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

J. Seeley, K. Maitland, A. Shali, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Common Inherited Mitochondrial Dna Mutations and Nucleoside Reverse Transcriptase Inhibitor-Induced Severe Hyperlactataemia in HIV-Infected Adults: An Exploratory Study

R. Ekong, N. Bradman, R. Weber, 2011, Antiviral therapy.

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

C. Katlama, D. Cooper, B. Grund, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial

A. Kambugu, N. Paton, A. Arenas-Pinto, 2016, Journal of NeuroVirology.

No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts

A. Winston, J. Lundgren, R. Price, 2018, AIDS.

Anxiety and depression symptoms in young people with perinatally acquired HIV and HIV affected young people in England

A. Winston, D. Gibb, A. Arenas-Pinto, 2018, AIDS care.

Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy

N. Beeching, M. Johnson, K. Sanders, 2016, AIDS.

Genital Secretion HIV RNA Shedding in HIV-Positive Patients on Ritonavir-Boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-Sectional Sub-Study from the PIVOT Trial

N. Beeching, S. Khoo, A. Clarke, 2020, Antiviral therapy.

Evaluation of Cerebrospinal Fluid Virological Escape in Patients on Long-Term Protease Inhibitor Monotherapy

N. Beeching, A. Clarke, I. Williams, 2017, Antiviral therapy.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production

P. Reiss, J. Kastelein, E. Stroes, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study

A. Milinkovic, M. Maini, A. Arenas-Pinto, 2015, BMC Infectious Diseases.

Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial

S. Walker, M. Sculpher, D. Dunn, 2016, PharmacoEconomics.

Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.

A. Milinkovic, S. Mauss, A. Arenas-Pinto, 2019, AIDS.

Host and disease factors are associated with cognitive function in European HIV‐infected adults prior to initiation of antiretroviral therapy

H. Amièva, A. Winston, A. Antinori, 2016, HIV medicine.

HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa

A. Walker, C. Kityo, N. Paton, 2017, Antiviral therapy.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

X. Golay, L. Haddow, A. Winston, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial

A. Kambugu, J. V. van Oosterhout, N. Paton, 2016, Journal of acquired immune deficiency syndromes.

Learning and memory function in young people with and without perinatal HIV in England

A. Winston, D. Gibb, A. Arenas-Pinto, 2022, PloS one.

Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment

A. Winston, J. Ainsworth, J. Day, 2014, PloS one.

Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe

A. Mocroft, O. Kirk, H. Furrer, 2013, European Respiratory Journal.

Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort

J. Neaton, C. Reilly, S. Safo, 2023, Journal of the American Heart Association.

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.

R. Paredes, H. Furrer, A. Phillips, 2023, NEJM evidence.

Increased risk of suicidal behaviour with use of efavirenz: results from the START trial

C. Katlama, D. Cooper, B. Grund, 2016 .

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.

Michael L. Nelson, Brad T. Sherman, I. Douglas, 2023, The Lancet. Respiratory medicine.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Title : Benefit of early versus deferred antiretroviral therapy on progression of liver fibrosis among people with HIV in the START randomized trial

S. Emery, C. Stephan, A. Arenas-Pinto, 2018 .

Hepatic steatosis in people older and younger than fifty who are living with HIV and HIV‐negative controls: A cross‐sectional study nested within the POPPY cohort

R. Gilson, A. Arenas-Pinto, N. Doyle, 2023, HIV medicine.

Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production

P. Reiss, J. Kastelein, E. Stroes, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Host and disease factors are associated with cognitive function in European HIV‐infected adults prior to initiation of antiretroviral therapy

F. Raffi, I. Williams, A. Arenas-Pinto, 2016, HIV medicine.

Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial

M. Gompels, A. Arenas-Pinto, Amanda Clarke, 2023, Viruses.

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial

J. Seeley, N. Klein, F. Fitzgerald, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

J. Ainsworth, M. Gompels, A. Arenas-Pinto, 2024, EClinicalMedicine.